Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

8.410 -0.060 (-0.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday ↗
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share... 
Via Benzinga
News headline image
FDA Lifts Clinical Hold On BioCryst's BCX9930 Program For Rare Blood Disorder ↗
 
Via Benzinga
News headline image
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday ↗
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
BioCryst's Voluntary Pause Of Rare Blood Disorder Trial Turns Into FDA Clinical Hold ↗
 
Via Benzinga
News headline image
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday. 
Via Benzinga
News headline image
BioCryst Pharmaceuticals: Q2 Earnings Insights ↗
  BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Alibaba, MercadoLibre And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗
 
Via Benzinga
News headline image
Stocks Rally as Major Indexes Look to End Losing Streaks ↗
All three major indexes are set to snap three consecutive weeks of losses on Friday, as stocks surge midday. 
Via Talk Markets
News headline image
BioCryst Gets FDA Fast Track Designation For Bone Formation Disorder Candidate ↗
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BioCryst Pharmaceuticals's (NASDAQ: BCRX) lead drug candidate BCX9250 for the prevention of heterotopic ossification... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
7 Cheap Biotech Stocks to Buy Now ↗
These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains. 
Via InvestorPlace
News headline image
9 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Recap: BioCryst Pharmaceuticals Q1 Earnings ↗
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
7 Top-Rated Biotech Stocks to Buy for Q2 ↗
In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill. 
Via InvestorPlace
News headline image
What 4 Analyst Ratings Have To Say About BioCryst Pharmaceuticals ↗
Within the last quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022 ↗
Upgrades 
Via Benzinga
News headline image
28 Biggest Movers From Yesterday ↗
Gainers HighPeak Energy, Inc. (NASDAQ: HPK) shares gained 31.76% to close at $28.83 on Wednesday, after CNBC’s Jim Cramer said the mid-cap company is an aggressive play on... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Oppenheimer Maintains Outperform Rating for BioCryst Pharmaceuticals, Lowers Price Target To $16 ↗
Oppenheimer has decided to maintain its Outperform rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) and lower its price target from $20.00 to $16.00. Shares of BioCryst Pharmaceuticals are trading down... 
Via Benzinga
News headline image
Why BioCryst Pharmaceuticals Stock Is Falling ↗
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Monday morning after BofA Securities downgraded the stock and Oppenheimer lowered its price target.  
Via Benzinga
News headline image
Mid-Afternoon Market Update: Nasdaq Falls 150 Points; Crude Oil Rises 2% ↗
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dropping more than 100 points on Friday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022 ↗
Upgrades 
Via Benzinga
News headline image
28 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Lyra Therapeutics, Inc. (NASDAQ: LYRA) shares climbed 33.3% to $5.78 as the company reported a private placement for gross proceeds of $110.5 million. TSR, Inc. (NASDAQ... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.